RADx Tech High-Performance Tests - CIMIT MAIN

Accelerating HealthTech Innovation

CIMIT is a trusted partner to organizations investing in medical innovation by providing efficient processes, leading market expertise and resources that enable economic progress and improved healthcare outcomes.

Learn More

We are thrilled to announce that we’ve been selected as one of the first spokes of the ARPA-H Investor Catalyst Hub network!

We are excited to be a part of this nationwide network dedicated to accelerating groundbreaking advances in science and medicine—all in pursuit of better health outcomes for everyone.

Learn more >

Funding Opportunities and Events

NIH Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge

$2 million in prizes to accelerate the development of diagnostic and monitoring technologies to reduce the risk of fetal morbidity and mortality and thus improve fetal and neonatal health outcomes.

Research and Innovation Translation Partnerships in Point-of-Care Technologies Conference and Technology Showcase

A two-day conference with researchers, technology developers, clinicians, and industry partners.

Center for Innovative NeuroTech Advancement

News and Annoucements

null RADx Tech High-Performance Tests

Tracy E McMahon

Modified 1 Year ago.

RADx Tech COVID-19 Funding Opportunity High-Performance COVID-19 Rapid Tests

The RADx Coordination Center at CIMIT, on behalf of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), is soliciting proposals to further advance next-generation (next-gen) over-the-counter (OTC) and point-of-care (POC) testing technologies for COVID-19 under its Rapid Acceleration of Diagnostics (RADx) fast-track program.

Under this RADx Tech Performance solicitation, NIBIB is seeking to accelerate the development of next Next-Gen COVID-19 diagnostic technologies with a focus on performance innovations: Innovations that provide significantly improved clinical and technical performance compared to current, best-in-class OTC/POC technologies. These platforms must also integrate universal design features in order to ensure the broadest possible ease of use and accessibility for all populations. Test platforms should return results quickly, demonstrate potential for integration with digital health reporting standards, and be capable of achieving regulatory clearance during both pandemic and non-pandemic periods.

Applications were due by October 31>

Connect with Us

JOIN OUR EMAIL LIST

Our Lasting Impact

As an early pioneer in managing translational research, CIMIT has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.